Adcendo ApS Advances ADCE-T02 Antibody-Drug Conjugate to Expansion Phase, ADCE-D01 Receives FDA Orphan Drug Status

Key Takeaways

• ADCE-T02, a tissue factor-targeted antibody-drug conjugate, has advanced to the cohort expansion portion of its Phase I Tiffany-01 study in advanced solid tumors
• ADCE-D01 received FDA Orphan Drug Designation, providing regulatory advantages for this first-in-class uPARAP-targeted ADC
• The company initiated dosing for ADCE-B05, expanding its pipeline of novel antibody-drug conjugates targeting undisclosed mechanisms

---

Adcendo ApS Reports Major Pipeline Milestones Across Multiple ADC Programs

Danish biotechnology company Adcendo ApS announced significant progress across its antibody-drug conjugate (ADC) portfolio, with lead candidate ADCE-T02 advancing to cohort expansion and ADCE-D01 receiving regulatory recognition from the FDA.

ADCE-T02 Advances in Solid Tumor Treatment

The company’s most advanced program, ADCE-T02, has entered the cohort expansion portion of the Tiffany-01 Phase I clinical trial. This tissue factor-targeted ADC represents a potential best-in-class approach for treating advanced solid tumors. The progression to expansion phase indicates the treatment has demonstrated acceptable safety and potential efficacy signals in the dose-escalation portion of the study.

Adcendo will present two publications highlighting ADCE-T02’s preclinical results at the 2026 AACR Annual Meeting, providing the scientific community with detailed data supporting the compound’s therapeutic potential.

FDA Grants Orphan Drug Status to ADCE-D01

The U.S. Food and Drug Administration awarded Orphan Drug Designation to ADCE-D01, a first-in-class ADC targeting uPARAP (urokinase plasminogen activator receptor-associated protein). This designation provides significant regulatory and commercial advantages, including seven years of market exclusivity upon approval, tax credits for clinical trial costs, and waived FDA user fees.

Orphan Drug Designation is granted to treatments for rare diseases affecting fewer than 200,000 people in the United States, suggesting ADCE-D01 targets a specific cancer indication with limited treatment options.

Pipeline Expansion with ADCE-B05

Adcendo has dosed the first patient in a Phase I trial of ADCE-B05, another first-in-class ADC directed against an undisclosed target. This milestone expands the company’s clinical-stage pipeline and demonstrates continued innovation in ADC development.

Market Implications

The antibody-drug conjugate market has experienced significant growth, with several ADCs receiving FDA approval in recent years. Adcendo’s progress across multiple programs positions the company as a notable player in this competitive space, particularly with its focus on novel targets and potential best-in-class approaches.

---

Frequently Asked Questions

What does cohort expansion mean for ADCE-T02 patients?

Cohort expansion means ADCE-T02 has shown promising safety and efficacy signals, allowing researchers to treat more patients at the recommended dose to gather additional data before advancing to Phase II trials.

When will ADCE-T02 be available to patients?

ADCE-T02 is currently in Phase I trials, meaning it will likely require several more years of clinical testing before potential FDA approval and commercial availability.

How do antibody-drug conjugates differ from traditional cancer treatments?

ADCs combine targeted antibodies with potent chemotherapy drugs, allowing precise delivery of cancer-killing agents directly to tumor cells while minimizing damage to healthy tissue.